{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:26:59Z","timestamp":1780730819606,"version":"3.54.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the cost-effectiveness of lurasidone compared with olanzapine and risperidone in the first-line treatment of patients with schizophrenia from a Chinese healthcare system perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A Markov model with 6-week cycle was constructed to reflect the disease progression of schizophrenia patients in the acute and maintenance phase. Probabilities of treatment discontinuation and adverse events in the acute phase were derived from the 6-week lurasidone clinical trial and a published network meta-analysis; long-term risks of relapse and discontinuation were estimated based on the 12-month lurasidone clinical trial and other treatment comparison studies. Cost inputs were derived from published literature and Chinese official documents, supplemented by expert opinions when necessary. Utility values were taken from published literature. Costs and quality-adjusted life-years (QALYs) were assessed over 15 years with a discount rate of 5% per year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Over a 15-year time horizon, lurasidone yielded an improvement of 0.197 QALYs with a cost saving of CN\u00a512,093 (US$1,753) vs. olanzapine and an improvement of 0.116 QALYs with a cost saving of CN\u00a56,781 (US$983) vs. risperidone. One-way sensitivity analyses demonstrated robust base-case results since all analyses yielded net monetary benefits &amp;gt;0 at a willingness-to-pay threshold of CN\u00a572,447.00 (US$10,499.57)\/QALY. Probabilistic sensitivity analyses suggested that lurasidone had 99.7, 99.9, and 100% probability of being cost-effective vs. olanzapine and risperidone at the conventional decision thresholds of 1, 2, and 3 times the Chinese per capita gross domestic product [namely CN\u00a572,447.00 (US$10,499.57)\/QALY, CN\u00a51,44,894.00 (US$20,999.13)\/QALY, and CN\u00a52,17,341.00 (US$31,498.70)\/QALY in 2020], respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Treatment with lurasidone was predicted to improve health outcomes and be a dominant strategy for patients with schizophrenia, compared with olanzapine and risperidone, in China.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.987408","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T12:28:05Z","timestamp":1663244885000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China"],"prefix":"10.3389","volume":"10","author":[{"given":"Jia","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S0140-6736(04)17061-X","article-title":"Suicide and the unique prevalence pattern of schizophrenia in mainland China: a retrospective observational study","volume":"364","author":"Phillips","year":"2004","journal-title":"Lancet."},{"key":"B2","unstructured":"GBD cause and risk summariesLancet2020"},{"key":"B3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/NDT.S96649","article-title":"Global economic burden of schizophrenia: a systematic review","volume":"12","author":"Chong","year":"2016","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2215-0366(18)30511-X","article-title":"Prevalence of mental disorders in China: a cross-sectional epidemiological study","volume":"6","author":"Huang","year":"2019","journal-title":"Lancet Psychiatry."},{"key":"B5","unstructured":"GBD Compare. IHME; [Cited 2021 Jul 31]"},{"key":"B6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1752-4458-7-26","article-title":"An investigation of economic costs of schizophrenia in two areas of China","volume":"7","author":"Zhai","year":"2013","journal-title":"Int J Ment Health Syst."},{"key":"B7","unstructured":"McDonaghMS\n            DanaT\n            SelphS\n            DevineEB\n            CantorA\n            BougatsosC\n          Treatments for Schizophrenia in Adults: A Systematic Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US)2017"},{"key":"B8","volume-title":"The Second Edition of Guidelines for the Prevention and Treatment of Schizophrenia","author":"Zhao","year":"2015"},{"key":"B9","unstructured":"Management of schizophrenia. Edinburgh: Scottish Intercollegiate Guidelines Network2013"},{"key":"B10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.4088\/JCP.v67n0408","article-title":"Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs","volume":"67","author":"Correll","year":"2006","journal-title":"J Clin Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.4088\/JCP.v68n1006","article-title":"Kan HJ, Carson WH, Marcus RN. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole vs olanzapine or placebo","volume":"68","author":"Italien","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1176\/appi.ajp.159.4.561","article-title":"Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia","volume":"159","author":"Sernyak","year":"2002","journal-title":"Am J Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diab Care."},{"key":"B14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"Am J Psychiatry."},{"key":"B15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1192\/bjp.bp.106.031716","article-title":"Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community","volume":"191","author":"Mackin","year":"2007","journal-title":"Br J Psychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.schres.2006.06.026","article-title":"Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline","volume":"86","author":"Nasrallah","year":"2006","journal-title":"Schizophr Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","article-title":"Efficacy and safety of lurasidone 80 and 160 mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial","volume":"145","author":"Loebel","year":"2013","journal-title":"Schizophr Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am J Psychiatry."},{"key":"B19","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","article-title":"Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study","volume":"47","author":"Nasrallah","year":"2013","journal-title":"J Psychiatr Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.schres.2013.03.013","article-title":"Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study","volume":"147","author":"Loebel","year":"2013","journal-title":"Schizophr Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40273-016-0405-0","article-title":"Cost-utility analysis of lurasidone vs. aripiprazole in adults with schizophrenia","volume":"34","author":"Rajagopalan","year":"2016","journal-title":"Pharmacoeconomics."},{"key":"B24","volume-title":"China Guidelines for Pharmacoeconomic Evaluations","author":"Liu","year":"2020"},{"key":"B25","unstructured":"Comparative discontinuation rates in patients treated with antipsychotics1819\n            DimaL\n            VasileD\n            VoicuVA\n          Therapeutics.162012"},{"key":"B26","unstructured":"Schizophrenia: core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update), Chapter 7.2. 2009"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2147\/NDT.S72367","article-title":"High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People's Republic of China","volume":"11","author":"Xiao","year":"2015","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/YIC.0000000000000111","article-title":"Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis","volume":"31","author":"Lin","year":"2016","journal-title":"Int Clin Psychopharmacol."},{"key":"B29","unstructured":"National Bureau of Statistics, [2020-07-14]"},{"key":"B30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.psychres.2014.04.042","article-title":"Prevalence of schizophrenia disability and associated mortality among Chinese men and women","volume":"220","author":"Liu","year":"2014","journal-title":"Psychiatry Res."},{"key":"B31","unstructured":"Inquiry of Drug Bid Information"},{"key":"B32","unstructured":"Medical Service Price Inquiry"},{"key":"B33","unstructured":"Medical Service Price Inquiry"},{"key":"B34","unstructured":"Price List of Current Medical Service Price in Changsha2020"},{"key":"B35","unstructured":"Price List of Medical Service Price Structure Adjustment Projects of Municipal Public Medical Institutions in Chengdu"},{"key":"B36","unstructured":"Notice on Printing and Distributing Price of Medical Service Projects of Public Medical Institutions in Liaoning Province"},{"key":"B37","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/jdi.12905","article-title":"Direct medical costs for patients with type 2 diabetes in 16 tertiary hospitals in urban China: a multicenter prospective cohort study","volume":"10","author":"Li","year":"2019","journal-title":"J Diabetes Investig."},{"key":"B38","unstructured":"Statistical Bulletin of National Economic and Social Development of the People's Republic of China in 2020"},{"key":"B39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1477-7525-6-105","article-title":"Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation","volume":"6","author":"Briggs","year":"2008","journal-title":"Health Qual Life Outcomes."},{"key":"B40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2147\/CEOR.S47990","article-title":"Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US","volume":"5","author":"O'Day","year":"2013","journal-title":"Clinicoecon Outcomes Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"689123","DOI":"10.3389\/fpubh.2021.689123","article-title":"Systematic review of methods and study quality of economic evaluations for the treatment of schizophrenia","volume":"9","author":"Wang","year":"2021","journal-title":"Front Public Health."}],"updated-by":[{"DOI":"10.3389\/fpubh.2022.1059495","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000}}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.987408\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T16:13:23Z","timestamp":1668010403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.987408\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":41,"alternative-id":["10.3389\/fpubh.2022.987408"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.987408","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fpubh.2022.1059495","asserted-by":"object"}]},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"article-number":"987408"}}